Germline MSH2 mutation was associated with higher risks of ovarian and endometrial cancer [25, 27], and the expression of MSH2 is associated with poor prognosis of uterine corpus endometrial carcinoma with a hazard ratio of 1.56 [38]. The gene discussed is MSH2; the disease is uterine corpus endometrial carcinoma.